scholarly journals Association of serum mineral parameters with mortality in hemodialysis patients: Data from the Korean end-stage renal disease registry

2018 ◽  
Vol 37 (3) ◽  
pp. 266-276 ◽  
Author(s):  
Yunmi Kim ◽  
Kyung Don Yoo ◽  
Hyo Jin Kim ◽  
Junga Koh ◽  
Yeonsil Yu ◽  
...  
Keyword(s):  
Renal Disease ◽  
End Stage Renal Disease ◽  
Hemodialysis Patients ◽  
Disease Registry ◽  
Stage Renal Disease ◽  
End Stage

scholarly journals SP644RELATIONSHIP BETWEEN SERUM URIC ACID AND MORTALITY IN KOREAN HEMODIALYSIS PATIENTS RESULTS FROM END-STAGE RENAL DISEASE REGISTRY

2017 ◽  
Vol 32 (suppl_3) ◽  
pp. iii353-iii354
Author(s):  
Chang Seong Kim ◽  
Minah Kim ◽  
Hong Sang Choi ◽  
Ha Yeon Kim ◽  
Eun Hui Bae ◽  
...  
Keyword(s):  
Uric Acid ◽  
Renal Disease ◽  
Serum Uric Acid ◽  
End Stage Renal Disease ◽  
Hemodialysis Patients ◽  
Disease Registry ◽  
Stage Renal Disease ◽  
End Stage

Depression in end-stage renal disease hemodialysis patients

2006 ◽  
Vol 2 (12) ◽  
pp. 678-687 ◽  
Author(s):  
Daniel Cukor ◽  
Rolf A Peterson ◽  
Scott D Cohen ◽  
Paul L Kimmel
Keyword(s):  
Renal Disease ◽  
End Stage Renal Disease ◽  
Hemodialysis Patients ◽  
Stage Renal Disease ◽  
End Stage

scholarly journals Correlation between Calcium Phosphorus Product and Mean Arterial Pressure among Hemodialysis Patients with End Stage Renal Disease

2020 ◽  
Vol 5 (1) ◽  
Author(s):  
Muhammad Nadeem ◽  
Mansoor Abbas Qaisar ◽  
Ali Hassan Al Hakami ◽  
Fateh Sher Chattah ◽  
Muhammad Muzammil ◽  
...  
Keyword(s):  
Mean Arterial Pressure ◽  
Arterial Pressure ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Hemodialysis Patients ◽  
Age Group ◽  
Calcium Phosphorus ◽  
The Mean ◽  
Stage Renal Disease ◽  
End Stage

Background: The mean arterial pressure serves as an expression of blood pressure in patients on chronic hemodialysis. Serum calcium phosphorus product is considered as a risk factor of vascular calcification that is associated with hypertension in the patients of end stage renal disease. The literature regarding this relationship is inconsistent therefore this study is designed to determine the correlation between calcium phosphorus product and mean arterial pressure among hemodialysis patients with end stage renal disease. Methods: A total of 110 patients of end stage renal disease on hemodialysis for at least one year, 20 to 60 years of age were included. Patients with primary or tertiary hyperparathyroidism, peripheral vascular disease, malignancy, hypertension secondary to any cause other than kidney disease were excluded. Mean arterial pressure was calculated according to the standard protocol in lying position. Blood samples for estimation of serum calcium and phosphorous were taken and was sent immediately to the laboratory for serum analysis. Results: Mean age was 44.17 ± 10.94 years. Mean calcium phosphorous product was 46.71 ± 7.36 mg/dl and mean arterial pressure was 103.61 ± 12.77 mmHg. The values of Pearson correlation co-efficient (r) were 0.863 for age group 20 to 40 years and 0.589 for age group 41 to 60 years. This strong positive correlation means that high calcium phosphorous product goes with high mean arterial pressure (and vice versa) for both the age groups. Conclusion: A strong positive relationship exists between the mean arterial pressure and calcium phosphorous product and is independent of patients’ age.

scholarly journals SP315ARCHITECT HEPATITIS C VIRUS (HCV) CORE ANTIGEN TEST: A HCV RNA SCREENING ALTERNATIVE IN END-STAGE RENAL DISEASE (ESRD) AND HEMODIALYSIS PATIENTS?

2018 ◽  
Vol 33 (suppl_1) ◽  
pp. i450-i450
Author(s):  
Rita Valério Alves ◽  
Rita Abrantes ◽  
Hernâni Gonçalves ◽  
Maria Leonor Gonçalves ◽  
Karina Lopes ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Hemodialysis Patients ◽  
Core Antigen ◽  
Hcv Rna ◽  
Antigen Test ◽  
Stage Renal Disease ◽  
End Stage

scholarly journals SUN-205 Prevalence of Cancer in End Stage Renal Disease Hemodialysis Patients

2020 ◽  
Vol 5 (3) ◽  
pp. S285
Author(s):  
F. AlKindi ◽  
S. Jamil ◽  
S. AlKaabi ◽  
M. Hakim ◽  
A. Chaaban ◽  
...  
Keyword(s):  
Renal Disease ◽  
End Stage Renal Disease ◽  
Hemodialysis Patients ◽  
Stage Renal Disease ◽  
End Stage ◽  
Prevalence Of Cancer

Influence of Recombinant Human Erythropoietin Therapy on Plasma Endothelin-1 Levels during Hemodialysis

2001 ◽  
Vol 24 (6) ◽  
pp. 367-373 ◽  
Author(s):  
I. Stefanidis ◽  
P.R. Mertens ◽  
P. Wurth ◽  
R. Bach ◽  
W. Makropoulos ◽  
...  
Keyword(s):  
Renal Disease ◽  
End Stage Renal Disease ◽  
Hemodialysis Patients ◽  
Recombinant Erythropoietin ◽  
Human Recombinant Erythropoietin ◽  
Endothelin 1 ◽  
Human Erythropoietin ◽  
Replacement Treatment ◽  
Stage Renal Disease ◽  
End Stage

The correction of anemia with human recombinant erythropoietin (rHuEPO) in end stage renal disease is associated with hypertension in about one third of hemodialysis patients. The pathogenesis of the rHuEPO-induced hypertension is still uncertain, though evidence of the involvement of endothelial cells has emerged. The aim of this study was to determine plasma endothelin-1 during hemodialysis and to compare the endothelin-1 levels in hemodialysis patients with and without rHuEPO substitution. Nineteen stable patients (13 male and 6 female, mean age 62 ± 11 years) with end stage renal disease were studied. Cuprophan dialysers (GFS 12®, Gambro, Lund, Sweden) were used for hemodialysis in all cases. rHuEPO (40U/kg s.c.) was administered to 10 patients. Blood pressure (BP; RR mmHg) and blood volume changes (ΔBV; hemoglobinometry %) were serially measured. Samples were taken before and every hour during hemodialysis. Plasma endothelin-1 was measured by ELISA (R&D Systems, Minneapolis, USA) and corrected for hemoconcentration. Endothelin-1 concentration was elevated before commencement of hemodialysis (1.16 ± 0.36 pg/ml) when compared to healthy controls (ref. 0.3 - 0.9) and increased to 1.47 ± 0.51 pg/ml by the end of the session (p<0.05). In patients under rHuEPO-substitution plasma endothelin-1 was higher when compared to patients without substitution before (1.25 ± 0.3 vs. 1.05 ± 0.3 pg/ml) and at the end of HD (1.62 ± 0.5 vs. 1.28 ± 0.3 pg/ml, p<0.05). There was no difference in BP and ΔBV between the two groups during treatment. Plasma endothelin-1 was higher in hemodialysis patients and there was a continuous rise in plasma endothelin-1 during a session. Comparison of two groups of hemodialysis patients with and without s.c. rHuEPO-replacement treatment revealed a significantly higher plasma endothelin-1 concentration in patients with s.c. rHuEPO treatment. However, the elevated endothelin-1 levels were not accompanied by arterial hypertension.

Sign in / Sign up

Export Citation Format

Share Document